🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 451 Beijing 25 Shenzhen 23 Zhongshan 17 Nanning 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281 Clear sponsor filter
Site location
Guangzhou451 Beijing25 Shenzhen23 Zhongshan17 Nanning17
All 55 locations
Target enrolment
to

Trials in this register

490 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study
NCT05457829Rhabdomyosarcoma, Child
Sun Yat-sen University
Phase 2
88
Guangzhou
2023-12-30
Recruiting
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
NCT06201065Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3
200
Guangzhou
2023-12-26
Recruiting
The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
NCT06433869Malignant Ascites
Sun Yat-sen University
Phase 2
60
Guangzhou
2023-12-14
Recruiting
SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx
NCT06219980SBRT
Sun Yat-sen University
Phase 2
25
Guangzhou
2023-12-07
Active, closed
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
NCT05975307Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy
Sun Yat-sen University
Phase 2
71
Guangzhou
2023-12-01
Active, closed
Guangzhou Preterm and Term Birth Cohort Study
NCT07756177Preterm Birth, Neurodevelopmental Disorders, Overweight, Obesity
Sun Yat-sen University
Observational
200
Guangzhou
2023-11-21
Recruiting
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
NCT05959356Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2
198
Foshan, Guangzhou, Guiyang
2023-11-09
Recruiting
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
NCT06041477Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
Sun Yat-sen University
Phase 3
540
Guangzhou
2023-10-31
Not yet open
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)
NCT05988372Locally Advanced Pancreatic Cancer
Sun Yat-sen University
Phase 2
50
Guangzhou
2023-10-23
Not yet open
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
NCT06063070Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer, Primary Peritoneal Cancer
Sun Yat-sen University
Phase 2
44
Guangzhou
2023-10-18
Recruiting
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
NCT06092957Nasopharyngeal Carcinoma, De-escalation Therapy
Sun Yat-sen University
Phase 3
504
Guangzhou
2023-10-09
Recruiting
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
NCT05949931Classic Hodgkin Lymphoma
Sun Yat-sen University
Phase 2
108
Guangzhou
2023-10-01
Recruiting
Evaluation of Phacogoniotomy in Medically-controlled POAG
NCT06201455Glaucoma, Open-Angle, Cataract Complicated, Goniotomy
Sun Yat-sen University
Not applicable
100
Guangzhou
2023-09-28
Active, closed
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
NCT05979961Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
464
Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan, Changsha
2023-09-07
Active, closed
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT05807880Nasopharyngeal Neoplasms
Sun Yat-sen University
Phase 2
59
Guangzhou
2023-09-01
Recruiting
Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients
NCT06043999Chemotherapy Effect, Rectal Cancer
Sun Yat-sen University
Not applicable
392
Guangzhou
2023-09-01
Recruiting
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
NCT06031285Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2
43
Guangzhou
2023-09-01
Active, closed
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
NCT06020885Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 1
18
Guangzhou
2023-08-31
Recruiting
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
NCT05962502Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2
54
Guangzhou
2023-08-24
Active, closed
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
NCT06577792Non Small Cell Lung Cancer
Sun Yat-sen University
Not applicable
620
Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing
2023-08-16
Active, closed
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
NCT05949944Peripheral T-cell Lymphoma
Sun Yat-sen University
Phase 1/2
44
Guangzhou
2023-08-15
Recruiting
Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
NCT05997719Non-small Cell Lung Cancer
Sun Yat-sen University
Observational
150
Guanzhou
2023-08-10
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Active, closed
Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes
NCT07003191Type 2 Diabetes
Sun Yat-sen University
Observational
2,600
Guangzhou
2023-08-02
Active, closed
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
NCT05587374Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Recruiting
Utilization of Transanal Endoscopy in the Treatment of Anastomotic Stenosis
NCT06036862Anastomotic Stenosis
Sun Yat-sen University
Not applicable
50
Guangzhou
2023-08-01
Recruiting
MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer
NCT06204484Colorectal Cancer
Sun Yat-sen University
Not applicable
349
Guangzhou
2023-07-26
Recruiting
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer
NCT05571644Colorectal Cancer
Sun Yat-sen University
Phase 2
143
Guangzhou
2023-07-10
Recruiting
PaCIFiC-CUP Classifies Cancer of Unknown Primary
NCT06140992Unknown Primary Tumors, DNA Methylation
Sun Yat-sen University
Observational
120
Guangzhou
2023-07-01
Recruiting
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
NCT05623267Limited Stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2/3
346
Guangzhou
2023-07-01
Recruiting
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
NCT05794971Colorectal Cancer Liver Metastases, Regorafenib
Sun Yat-sen University
Phase 3
126
Guangdong
2023-06-10
Active, closed
Effect of IOP Lowering on Progressive HM
NCT05850936High Myopia, Intraocular Pressure
Sun Yat-sen University
Not applicable
152
Guangzhou
2023-06-01
Recruiting
Effects of Digital Therapeutic in Whole Process Management of Lung Cancer
NCT06230445Application of Digital Therapeutic in Lung Cancer Whole Process Management
Sun Yat-sen University
Phase 3
900
Guangzhou
2023-06-01
Recruiting
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
NCT07644897Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor
Sun Yat-sen University
Phase 2
55
Guangzhou, Shenzhen
2023-05-30
Recruiting
Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
NCT05877872Nasopharyngeal Carcinoma, De-escaltion Therapy
Sun Yat-sen University
Phase 3
424
Guangzhou
2023-05-20
Recruiting
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
NCT06451211Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach
Sun Yat-sen University
Phase 2
53
Guangzhou
2023-05-17
Active, closed
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
NCT05824468Cervical Cancer, Cervical Carcinoma
Sun Yat-sen University
Phase 2
30
Guangzhou
2023-05-10
Active, closed
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
NCT05824481Endometrial Cancer, Endometrial Adenocarcinoma
Sun Yat-sen University
Phase 2
32
Guangzhou
2023-05-08
Recruiting
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
NCT05854849Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
244
Guangzhou
2023-05-01
Recruiting
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
NCT05918094Gastric Cancer
Sun Yat-sen University
Phase 3
540
Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai
2023-04-30
Not yet open
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
NCT05780294Nasopharyngeal Carcinoma, Leucogen, Chemotherapy, Myelosuppression
Sun Yat-sen University
Phase 3
132
Guangzhou
2023-04-01
Recruiting
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
NCT05768490Brain Metastases, Radiotherapy, EGFR Activating Mutation
Sun Yat-sen University
Phase 3
232
Guangdong
2023-03-15
Recruiting
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
NCT05751343Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2
55
Guangzhou
2023-03-09
Recruiting
Evaluation of COVID-19 Immune Barrier and Reinfection Risk
NCT05774093COVID-19 Infection, Immunization; Infection
Sun Yat-sen University
Observational
300
Guangzhou
2023-03-06
Recruiting
Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
NCT06788353Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma
Sun Yat-sen University
Observational
500
Guangzhou
2023-03-01
Recruiting
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
NCT05768503Metastatic Microsatellite-stable Colorectal Cancer
Sun Yat-sen University
Phase 3
176
Hefei, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Nanchang, Shanghai
2023-03-01
Not yet open
SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
NCT05718232Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3
136
Guangzhou
2023-03
Recruiting
Safety and Efficacy of Two-step Radical Prostatectomy
NCT05722392Prostate Cancer
Sun Yat-sen University
Observational
30
Guangzhou
2023-02-15
Active, closed
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
NCT05426005Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H)
Sun Yat-sen University
Phase 1/2
28
Guangzhou
2023-02-07
Recruiting
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
NCT05472948Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic
Sun Yat-sen University
Phase 2
36
Guangzhou
2023-02-01
Active, closed
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT05481476Pancreatic Neoplasms
Sun Yat-sen University
Phase 2
32
Guangzhou
2022-12-12
Not yet open
A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
NCT05622474Nasopharyngeal Carcinoma
Sun Yat-sen University
Not applicable
236
Guangzhou
2022-11-30
Active, closed
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
NCT05524168Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
41
Guangzhou
2022-11-25
Active, closed
Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial
NCT05531916Nasopharyngeal Carcinoma, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Sun Yat-sen University
Not applicable
182
Guangzhou
2022-11-21
Recruiting
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
NCT05357846Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer
Sun Yat-sen University
Phase 3
422
Guangzhou
2022-11-01
Recruiting
A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
NCT05718492Hepatocellular Carcinoma
Sun Yat-sen University
Not applicable
100
Guangzhou
2022-10-18
Not yet open
Effect of Prebiotics on Blood Pressure Management
NCT05364736Hypertension, Gastrointestinal Microbiome
Sun Yat-sen University
Not applicable
100
Guangzhou
2022-10-17
Recruiting
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
NCT06551220Metastatic Breast Cancer
Sun Yat-sen University
Observational
800
Fuzhou, Dongguan, Foshan, Guangzhou, Shantou, Shaoguan, Shenzhen, Zhongshan
2022-10-10
Active, closed
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
NCT05520619Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2
114
Guangzhou
2022-09-15
Active, closed
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
NCT05491811Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 2
47
Guangzhou
2022-08-01
Recruiting
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
NCT05727163Colorectal Cancer Metastatic
Sun Yat-sen University
Phase 2
194
Guangzhou
2022-07-29
Recruiting
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
NCT05476432Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3
300
Foshan, Guangzhou
2022-07-26
Active, closed
Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)
NCT05453435Resolved Hepatitis B, CD20 Positive B-cell Lymphoma
Sun Yat-sen University
Phase 2
84
Guangzhou
2022-07-15
Recruiting
Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
NCT05447169Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
11,625
Guangzhou
2022-07-10
Recruiting
The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer
NCT05984485Rectal Cancer
Sun Yat-sen University
Phase 3
766
Chongqing, Guangzhou, Hengyang, Shenyang, Xi'an, Nanchong
2022-07-05
Recruiting
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
NCT05444478Hepatocellular Carcinoma, Microwave Ablation, Liver Cancer, Lenvatinib
Sun Yat-sen University
Not applicable
274
Changsha
2022-07-01
Active, closed
Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma
NCT05464433Extranodal Natural Killer T Cell Lymphoma
Sun Yat-sen University
Phase 1/2
46
Beijing, Dalian, Guangzhou, Nanchang
2022-06-23
Recruiting
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05430399Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Phase 3
349
Guangzhou, Hunan
2022-06-21
Active, closed
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
NCT05211232Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
450
Zhanjiang, Wuzhou, Guiyang, Changsha
2022-06-10
Recruiting
Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
NCT05397769Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemotherapy, PD-L1
Sun Yat-sen University
Phase 2
36
Guangzhou
2022-06-08
Recruiting
The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
NCT06019455Lung Cancer, Esophageal Cancer
Sun Yat-sen University
Observational
500
Guangzhou
2022-06-01
Recruiting
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
NCT05352321Nasopharyngeal Carcinoma
Sun Yat-sen University
Not applicable
264
Guangzhou
2022-06-01
Not yet open
Umbrella Biomarker-Guided Therapy in NPC
NCT04605562Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
206
Guangzhou
2022-06
Active, closed
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
NCT05201859Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
150
Guangzhou
2022-05-17
Active, closed
Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain
NCT05304468Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
452
Guangzhou
2022-05-11
Recruiting
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
NCT05334277Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2
280
Changchun, Chengdu, Dongguan, Dongyang, Foshan, Guangzhou, Hangzhou, Jiangmen
2022-05-06
Recruiting
Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance
NCT05528783Colorectal Cancer
Sun Yat-sen University
Observational
200
Guangzhou
2022-04-25
Active, closed
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer
NCT05319574Carcinoma, Non-Small-Cell Lung
Sun Yat-sen University
Phase 2
46
Guangzhou
2022-04-24
Recruiting
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
NCT05342792Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
556
Guangzhou
2022-04-17
Recruiting
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
NCT05340491Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Recruiting
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
NCT05367206Cervical Cancer, Neoadjuvant Chemotherapy, Bulky Neoplasm
Sun Yat-sen University
Phase 3
280
Guangzhou
2022-03-14
Not yet open
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05172518Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Phase 3
512
Guangzhou
2022-03-01
Active, closed
Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
NCT05220267Non Clear Cell Renal Carcinoma
Sun Yat-sen University
Phase 2
44
Guangzhou
2022-02-28
Active, closed
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05193617Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
104
Guangzhou
2022-01-20
Active, closed
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
NCT05198609Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3
214
Guangzhou
2022-01-17
Active, closed
Predictive Value of Postoperative Circulating Tumor DNA Monitoring for Colorectal Cancer Recurrence
NCT06143644Colorectal Cancer
Sun Yat-sen University
Observational
220
Guangzhou
2022-01-15
Active, closed
Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)
NCT06618014Breast Cancer, Triple Negative Breast Cancer
Sun Yat-sen University
Phase 2
51
Guangzhou
2022-01-11
Recruiting
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
NCT07516678Neuroblastoma
Sun Yat-sen University
Observational
200
Guangzhou
2022-01-01
Recruiting
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
NCT05468242Stage III Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2
116
Guangzhou
2022-01-01
Recruiting
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors
NCT06760117Pediatric Solid Tumor
Sun Yat-sen University
Phase 1
39
Guangzhou
2022-01-01
Recruiting
Multi-model Image of Doxycycline in TAO
NCT05112211Thyroid Associated Ophthalmopathy
Sun Yat-sen University
Not applicable
20
Guangzhou
2022-01-01
By invitation
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator
NCT05338866Rectal Cancer
Sun Yat-sen University
Observational
58
Guangzhou
2022-01-01
Recruiting
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
NCT05236972Colorectal Carcinoma
Sun Yat-sen University
Phase 3
323
Guangzhou
2022-01-01
By invitation
A Cohort Study on Cardiovascular and Cerebrovascular Outcomes
NCT07178015Stroke, Atheroscleroses
Sun Yat-sen University
Observational
855
Guangzhou
2021-12-30
Recruiting
Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma
NCT05170503Esophagogastric Junction Adenocarcinoma
Sun Yat-sen University
Phase 2
37
Guangzhou
2021-12-29
Active, closed
Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
NCT05106777Sarcoma
Sun Yat-sen University
Phase 2
47
Guangzhou
2021-12-10
Recruiting
The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study
NCT04957901Lymphoma
Sun Yat-sen University
Observational
60
Guangzhou
2021-12-01
Recruiting
Minocycline for Chronic Autoimmune Uveitis
NCT05474729Minocycline, Uveitis, Retinal Degeneration
Sun Yat-sen University
Phase 1/2
10
Guangzhou
2021-12-01
Recruiting
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
NCT05194878Colon Cancer Stage II, Colon Cancer Stage III
Sun Yat-sen University
Phase 3
840
Guangzhou
2021-12-01
Recruiting
Comparison of Posterior Continuous Curvilinear Capsulorhexis With or Without Anterior Vitrectomy
NCT05136209Congenital Cataract
Sun Yat-sen University
Not applicable
50
Guangzhou
2021-11-01
Rows per page Showing 301–400 of 490
Previous 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 490 of those studies that match the filters currently applied.

How many clinical trials are recruiting in China?

305 of the 490 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 101 have not yet opened recruitment, 76 are active but closed to new participants, and 8 are enrolling by invitation only. Eligibility for any study is decided by its study team.

→

Browse trials by condition

Nasopharyngeal Carcinoma (56) Hepatocellular Carcinoma (23) Nasopharyngeal Cancinoma (NPC) (18) Colorectal Cancer (14) Breast Cancer (11) Rectal Cancer (9) Chemotherapy (9) Nasopharyngeal Carcinoma (NPC) (9) Radiotherapy (8) Surgery (7) Non-small Cell Lung Cancer (7) Colorectal Cancer Metastatic (6) Immunotherapy (6) Advanced Hepatocellular Carcinoma (6) Neoadjuvant Therapy (6)
→

Browse trials by site location

Guangzhou (451) Beijing (25) Shenzhen (23) Zhongshan (17) Nanning (17) Fuzhou (16) Foshan (15) Dongguan (14) Shantou (13) Zhanjiang (12) Nanchang (12) Changsha (12) Wuhan (12) Zhuhai (11) Chengdu (10)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.